Metastatic Castrate Resistant Prostate Cancer Clinical Trial
Official title:
A Prospective, Multicenter, Randomized, Double Blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Docetaxel to Placebo in Combination With Docetaxel in First Line Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.
The objective of this study is to evaluate the efficacy and safety of masitinib in combination with docetaxel and prednisone with respect to placebo in combination with docetaxel and prednisone in the treatment of first line metastatic Castrate Resistant Prostate Cancer (mCRPC). Approximately 580 patients will be randomized in 2 groups with a ratio 1:1. The primary outcome measure is progression free survival. Masitinib is a selective tyrosine kinase inhibitor that is thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04038502 -
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
|
Phase 2 | |
| Terminated |
NCT03729596 -
MGC018 With or Without MGA012 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03737370 -
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
| Terminated |
NCT01732549 -
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
|
Phase 2 | |
| Completed |
NCT01090765 -
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
|
Phase 1/Phase 2 | |
| Suspended |
NCT03236688 -
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
|